Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation.

Panopoulos, Stylianos T; Tektonidou, Maria G; Bournia, Vasiliki-Kalliopi; Laskari, Katerina; Sfikakis, Petros P

Panopoulos, Stylianos T; Tektonidou, Maria G; Bournia, Vasiliki-Kalliopi; Laskari, Katerina; Sfikakis, Petros P.

Afiliación

Panopoulos ST; Joint Rheumatology Program, First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Greece. sty.panopoulos@gmail.com.
Tektonidou MG; Joint Rheumatology Program, First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Greece.
Bournia VK; Joint Rheumatology Program, First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Greece.
Laskari K; Joint Rheumatology Program, First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Greece.
Sfikakis PP; Joint Rheumatology Program, First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Greece.

Clin Exp Rheumatol ; 39 Suppl 131(4): 29-33, 2021.

Article en En | MEDLINE | ID: mdl-33200737

Asunto(s)

Trasplante de Células Madre Hematopoyéticas; Esclerodermia Difusa; Esclerodermia Sistémica; Ciclofosfamida/uso terapéutico; Humanos; Esclerodermia Sistémica/diagnóstico; Esclerodermia Sistémica/tratamiento farmacológico; Trasplante Autólogo

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerodermia Sistémica / Trasplante de Células Madre Hematopoyéticas / Esclerodermia Difusa Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Humans Idioma: En Revista: Clin Exp Rheumatol Año: 2021 Tipo del documento: Article País de afiliación: Grecia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google